Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
- PMID: 30318013
- PMCID: PMC6864602
- DOI: 10.2174/1874467211666181010154139
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Abstract
Background: Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the Peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly understood.
Objectives: This article aims to fully review pharmacokinetics and pharmacodynamics of mescaline, focusing on the in vivo and in vitro metabolic profile of the drug and its implications for the variability of response.
Methods: Mescaline pharmacokinetic and pharmacodynamic aspects were searched in books and in PubMed (U.S. National Library of Medicine) without a limiting period. Biological effects of other compounds found in peyote were also reviewed.
Results: Although its illicit administration is less common, in comparison with cocaine and Cannabis, it has been extensively described in adolescents and young adults, and licit consumption often occurs in religious and therapeutic rituals practiced by the Native American Church. Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization and psychoses. Moreover, as a phenethylamine derivative, signs and symptoms are consistent with a sympathomimetic effect. Mescaline is mainly metabolized into trimethoxyphenylacetic acid by oxidative deamination but several minor metabolites with possible clinical and forensic repercussions have also been reported.
Conclusion: Most reports concerning mescaline were presented in a complete absence of exposure confirmation, since toxicological analysis is not widely available. Addiction and dependence are practically absent and it is clear that most intoxications appear to be mild and are unlikely to produce lifethreatening symptoms, which favors the contemporary interest in the therapeutic potential of the drugs of the class.
Keywords: Mescaline; metabolism; peyote; pharmacodynamics; pharmacokinetics; toxicity..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Figures
![Fig. (1)](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6864602/bin/CMP-12-184-F1.gif)
![Fig. (2)](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6864602/bin/CMP-12-184-F2.gif)
![Fig. (3)](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6864602/bin/CMP-12-184-F3.gif)
![Fig. (4)](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6864602/bin/CMP-12-184-F4.gif)
![Fig. (5)](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6864602/bin/CMP-12-184-F5.gif)
Similar articles
-
An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture.Molecules. 2023 Dec 5;28(24):7942. doi: 10.3390/molecules28247942. Molecules. 2023. PMID: 38138432 Free PMC article. Review.
-
Mescaline: The forgotten psychedelic.Neuropharmacology. 2023 Jan 1;222:109294. doi: 10.1016/j.neuropharm.2022.109294. Epub 2022 Oct 14. Neuropharmacology. 2023. PMID: 36252614 Review.
-
Elucidation of the mescaline biosynthetic pathway in peyote (Lophophora williamsii).Plant J. 2023 Nov;116(3):635-649. doi: 10.1111/tpj.16447. Epub 2023 Sep 7. Plant J. 2023. PMID: 37675639
-
The analysis and distribution of mescaline in postmortem tissues.J Anal Toxicol. 2003 Sep;27(6):381-2. doi: 10.1093/jat/27.6.381. J Anal Toxicol. 2003. PMID: 14516493
-
Dark Classics in Chemical Neuroscience: Mescaline.ACS Chem Neurosci. 2018 Oct 17;9(10):2448-2458. doi: 10.1021/acschemneuro.8b00215. Epub 2018 Jun 8. ACS Chem Neurosci. 2018. PMID: 29847089 Review.
Cited by
-
An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture.Molecules. 2023 Dec 5;28(24):7942. doi: 10.3390/molecules28247942. Molecules. 2023. PMID: 38138432 Free PMC article. Review.
-
Drug-drug interactions involving classic psychedelics: A systematic review.J Psychopharmacol. 2024 Jan;38(1):3-18. doi: 10.1177/02698811231211219. Epub 2023 Nov 20. J Psychopharmacol. 2024. PMID: 37982394 Free PMC article. Review.
-
Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.Addict Behav Rep. 2023 Aug 12;18:100513. doi: 10.1016/j.abrep.2023.100513. eCollection 2023 Dec. Addict Behav Rep. 2023. PMID: 37649653 Free PMC article.
-
A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.Int J Mol Sci. 2023 Aug 7;24(15):12513. doi: 10.3390/ijms241512513. Int J Mol Sci. 2023. PMID: 37569888 Free PMC article. Review.
-
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.Neuropsychopharmacology. 2023 Oct;48(11):1659-1667. doi: 10.1038/s41386-023-01607-2. Epub 2023 May 25. Neuropsychopharmacology. 2023. PMID: 37231080 Free PMC article. Clinical Trial.
References
-
- Bogenschutz M.P., Johnson M.W. Classic hallucinogens in the treatment of addictions. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2016;64:250–258. - PubMed
-
- Nichols D.E. Hallucinogens. Pharmacol. Ther. 2004;101:131–181. - PubMed
-
- Olive M.F., Triggle D.J. Drugs the straight facts: Peyote and mescaline. New York: Chelsea House; 2007.
-
- Dinis-Oliveira R.J. Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metab. Rev. 2017;49:84–91. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources